Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 clazakizumab in chronic active antibody-mediated rejection after kidney transplant
2018-003682-34Phase 3Completed
- Sponsor
- Vitaeris Inc.
- Start
- Mar 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of clazakizumab in Chronic active antibody-mediated rejection (caABMR), sponsored by Vitaeris Inc. Primary endpoint: All-cause composite allograft loss due to chronic active antibody-mediated rejection. Started Mar 2019; status: completed.
02
Drugs
clazakizumab
03
Conditions
Chronic active antibody-mediated rejection (caABMR)
Beyond the preview
Go deeper on 2018-003682-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003682-34.